New Omicron sub-variant with 70+ mutations under global watch, but experts say no cause for panic yet.
A new variant of SARS-CoV-2, the virus responsible for COVID-19, is drawing global attention after being detected in at least 23 countries. Known as BA.3.2 and nicknamed “Cicada,” the variant is being closely monitored by health authorities, including the World Health Organization and the Centers for Disease Control and Prevention. Despite its rapid spread and high number of mutations, early data suggests that it does not cause more severe illness than previous strains.
The BA.3.2 variant is a sub-lineage of the Omicron family, which dominated global infections during the later stages of the pandemic. It was first identified in South Africa in November 2024 but remained largely unnoticed for months before emerging more prominently in 2025. The nickname “Cicada” reflects its pattern of staying under the radar before appearing more widely—much like the insect known for its periodic emergence.
One of the primary reasons scientists are paying close attention to BA.3.2 is its unusually high number of mutations, particularly in the spike protein. Reports indicate that the variant carries around 70 to 75 spike mutations—significantly higher than earlier variants like Omicron, which had around 30, and Delta, which had about 10. These mutations may help the virus evade immune protection from past infections or vaccinations, raising concerns about reinfections.
According to surveillance data from the CDC, BA.3.2 cases have been increasing since late 2025. The variant has been detected through clinical samples, international travel screenings, and wastewater monitoring systems across multiple regions. It has now spread across continents, including Africa, Europe, North America, Asia, and Oceania. Countries such as the United States, Germany, the Netherlands, and Mozambique have reported cases, though the overall proportion remains low in many areas.
Despite its global presence, experts emphasize that BA.3.2 has not led to a surge in hospitalizations or deaths. Studies, including analyses published in The Lancet, suggest that while the variant shows strong immune escape properties in laboratory conditions, it may be less efficient at binding to the ACE2 receptors in lung cells. This could explain why it has not resulted in more severe disease outcomes.
In terms of symptoms, BA.3.2 infections appear similar to those caused by earlier Omicron variants. Common symptoms include sore throat, fever, fatigue, cough, body aches, and a runny nose. Some individuals may also experience headaches, nausea, or mild gastrointestinal issues. Severe symptoms such as shortness of breath have been reported in fewer cases.
Health experts believe that while the variant may spread more easily in populations with partial immunity, its real-world transmission advantage remains moderate. It has not yet replaced dominant circulating strains globally, which is a key factor in determining its long-term impact.
Vaccination continues to play a crucial role in protection. While BA.3.2 may reduce the effectiveness of vaccines in preventing infection, current data indicates that vaccines still offer strong protection against severe illness, hospitalization, and death. Health agencies continue to recommend staying up to date with vaccinations and booster doses.
In India, there is currently no evidence of a major outbreak linked to BA.3.2. However, experts warn that international travel could introduce the variant into the country. Monitoring efforts by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) remain essential to track any emerging threats.
Overall, while the BA.3.2 “Cicada” variant is a cause for scientific vigilance, there is no immediate reason for alarm. Experts stress the importance of continued surveillance, vaccination, and public awareness to manage any potential risks effectively.
Read more…iPhone 18 Pro Launch Soon: Features, Price, Colours
